Recce Pharmaceuticals Ltd (ASX: RCE) shares are being hammered on Friday after the ASX biotech company released an update.
At the time of writing, the Recce share price is down a massive 18.48% to 37.5 cents.
That leaves the ASX healthcare stock down 40% since the start of 2026, wiping out a large chunk of its earlier momentum. However, the stock is still up 25% over the past year.
The latest announcement appears to have rattled investors, raising questions about Recce's funding needs and whether the market is losing patience.
Recce is developing synthetic anti-infectives designed to address antimicrobial-resistant infections.
Image source: Getty Images
The capital raise behind the sell-off
According to the release, Recce has received firm commitments to raise $4 million before costs through an institutional placement.
The company will issue 10 million new shares at 40 cents per share.
The placement price appears to be the sticking point for investors. It is slightly above the current share price, but still well below where Recce shares were trading before the update.
Reece is also launching a share purchase plan (SPP) to raise up to another $4 million. Eligible shareholders can apply for up to $30,000 worth of new shares on the same terms as the placement.
Investors taking part in the placement and SPP will also receive one free attaching option for every two new shares issued. These options will have an exercise price of 60 cents and expire on 30 June 2027.
On top of that, holders who exercise those attaching options will receive two piggyback options, with an exercise price of $1 and an expiry date of 30 June 2028.
Where the money is going
Recce said the funds will be used across several parts of the business.
The cash will help strengthen its balance sheet, support commercial licensing work with a leading Middle Eastern pharmaceutical company, and fund clinical trials.
The company pointed to ongoing work on diabetic foot infections, including a Phase 3 registration trial in Indonesia and another in Australia.
Funds will also go toward activities linked to an Investigational New Drug application with the US Food and Drug Administration (FDA) and Indonesia's BPOM.
After the offer, Recce expects pro forma cash liquidity of approximately $29.5 million before offer costs.
Can Recce win back investors?
Capital raisings can be very hard for smaller biotech companies, especially when commercial revenue is still limited.
Recce's market capitalisation is now about $108 million, so a potential $8 million raise is definitely meaningful.
The company now needs to show that this funding can support clinical progress, regulatory work, and commercial deals.
Until then, it looks like investors are staying on the sidelines.
